Recent studies have shown that the cell proliferation antigen Ki-67 is not required for cell proliferation. Here, we demonstrate that Ki-67 enables implementation of transcriptional programmes conferring cellular plasticity, and is required for each step of tumour initiation, growth and metastasis. Ki-67 knockout causes global transcriptome remodelling, which, in mammary carcinoma cells, inhibits the epithelial-mesenchymal transition in a polycomb-repressive complex 2-dependent manner. This results in suppression of stem cell characteristics and sensitisation to various drug classes. Cancer 2 cells lacking Ki-67 proliferate normally in vivo, but tumour growth is inhibited due to disrupted angiogenesis, and metastasis is abrogated. Finally, mice lacking Ki-67 are resistant to chemical or genetic induction of intestinal tumourigenesis. Thus, Ki-67, which is expressed in all proliferating cancer cells, confers the plasticity required for different steps of carcinogenesis.
between Mki67 -/-4T1 (epithelial) and NIH/3T3 (mesenchymal) cells (Fig. 1C , Tables S1, S2) in accordance with our hypothesis that, by maintaining chromatin organisation, Ki-67 ensures global gene expression programmes in different cell types rather than directly regulating specific genes.
We then investigated whether the extensive transcriptome changes seen in cancer cells upon Ki-67 knockout deregulate transcription programmes involved in tumourigenesis. Pathway analysis of highly deregulated genes revealed upregulation of Notch targets and downregulation of genes involved in the inflammatory response, Wnt pathway, the epithelial-mesenchymal transition (EMT) and xenobiotic metabolism ( Fig.   1D ), which we validated by qRT-PCR ( Fig. 1E ). Downregulated genes were enriched in targets of nuclear factor erythroid 2-related factor 2 (NFE2L2), one of the major orchestrators of responses to oxidative stress; polycomb-repression complex 2 (PRC2), which mediates H3K27me3 and is a well-characterised regulator of the EMT (20, 21) ; the pluripotency factors Nanog and Sox2; and interferon regulatory factor 8 (IRF8) (Fig. 1F ).
All of these pathways have previously been implicated in tumourigenesis.
Ki-67 enables the epithelial-mesenchymal transition and cell plasticity.
We next investigated the biological relevance of these transcriptome alterations.
Importantly, although the Notch pathway is oncogenic in T cell acute lymphoid leukaemia, it can act as a tumour suppressor in specific cellular contexts (22) , can block Wnt signalling (23, 24 ) (a driver of tumourigenesis, cell stemness and the EMT) and induce drug resistance (25) . We confirmed Notch pathway upregulation at the protein level ( Fig. 2A) . We also confirmed that Ki-67 knockout 4T1 cells had lost expression of the mesenchymal marker vimentin but upregulated E-cadherin, and had a more epithelial morphology (Fig. 2B, C) , indicative of a loss of EMT. Since the EMT is closely associated with a stem-like state (26) (27) (28) , we next analysed aldehyde dehydrogenase activity, a marker of stem and progenitor cells (29, 30) . This was strongly reduced in 4T1 Ki-67 knockout cells ( Fig. 2D ), suggesting a loss of stem-like character. In agreement, the ability to form spheroids in the absence of adhesion to a surface (26, 31) was also strongly reduced ( Fig. 2E ).
In addition to stem-like characteristics, the EMT has also been associated with resistance to chemotherapeutic drugs (32) . We noticed that 26 genes involved in drug metabolism were downregulated in Ki-67 knockout 4T1 cells, while only one was upregulated, suggesting that Ki-67 expression might determine sensitivity to chemotherapeutic drugs (Fig. 1D, Fig. S2A ). To test this, we performed an automated gene-drug screen using the Prestwick chemical library, composed of 1283 FDAapproved small molecules. We also included salinomycin, a positive control found to target cancer stem cells (33) , and 6-thioguanine, which was originally used to isolate 4T1 cells (18) . Control 4T1 cells were sensitive to 102 drugs at 10µM concentration, while the two Mki67 -/clones were sensitive to 99 and 98 respectively, with 82 hits common to the three cell lines ( Fig. S2B ; Supporting Data S1). This suggests that Ki-67 loss does not qualitatively alter the drug-sensitivity profiles. We next determined the IC 50 of 10 common hits used in cancer therapy. Importantly, Mki67 -/cells were markedly more sensitive to all the molecules tested ( Fig. 2F ). As such, by supporting expression of xenobiotic metabolism genes, Ki-67 provides cancer cells with a degree of protection against drugs used in therapies.
We previously found that in human osteosarcoma U2OS cells, Ki-67 binds to the essential PRC2 component SUZ12 (11) . To test whether the repression of the EMT in Ki-67 knockout depends on PRC2, we disrupted Suz12 or Ezh2 in WT and Mki67 -/-4T1 cells using CRISPR-Cas9 (Fig. 2G ). This partially rescued expression of vimentin ( Fig. 2G ), suggesting that loss of Ki-67 releases a pool of PRC2 which can then repress target genes, including EMT genes.
Ki-67 is essential for normal mammary tumour growth and metastasis.
Hybrid EMT states are important for tumourigenesis (34) (35) (36) , and most evidence supports an essential role for the EMT in metastasis (37, 38) . To determine the physiological consequences of Ki-67 loss for tumourigenesis, we engrafted WT and Ki-6 67 knockout 4T1 cells orthotopically into mouse mammary fat pads. Since Ki-67 knockout caused alteration of inflammatory response genes ( Fig. 1D ), we used athymicnude and NOD/SCID mice, allowing us to assess roles of Ki-67 in tumour growth and metastasis without confounding effects of a potentially altered immune response. RNAseq of early-stage tumours from WT and Ki-67 mutant 4T1 cells grafted into nude mice showed that Ki-67-dependent transcriptome changes were generally preserved in vivo Table S3 ). As assessed by PCNA staining, cell proliferation in vivo was unaffected by loss of Ki-67, but tumours from Mki67 -/-4T1 cells grew significantly slower than from Ki-67-expressing 4T1 cells in both types of immunodeficient mice ( Fig. 3B-D) .
Control 4T1 cells metastasised within 3-4 weeks in nude mice, but metastases were largely absent at this point in mice bearing Mki67 -/-4T1 cells ( Fig. 3E ). We quantified micrometastases by dissociating lung tissue after 3 weeks and growing cells in the presence of 6-thioguanine, to which 4T1 cells are resistant. The number of metastatic cells that formed colonies was reduced nearly 100-fold in Ki-67 knockouts (Fig. 3F ). This points to an essential requirement for Ki-67 in metastasis, in accordance with its role in enabling the EMT.
To assess the generality of requirement for Ki-67 in tumour growth in human cancer cells, we disrupted the MKI67 gene by CRISPR-Cas9 in human MDA-MB-231 triple negative breast cancer cells ( Fig. S3A -D). As expected, MKI67 -/cells proliferated normally in vitro ( Fig. S3C, D) . In contrast, tumours from xenografts in nude mice grew much slower than controls ( Fig. 4A ). Cell proliferation was normal, as expected ( Fig. 4B ), but, while a regular thin fibrovascular capillary network was present in WT tumours, this was disorganised and irregular in MKI67 -/tumours, suggesting defective angiogenesis ( Fig. 4C ). In accordance, mutant tumours showed increased oedema of lymphatic vessels, indicative of slow blood flow, and a larger necrotic area. Thus, Ki-67 is required to promote tumour growth not through sustaining cell proliferation, but by inducing angiogenesis.
Mice lacking Ki-67 are resistant to intestinal tumourigenesis.
The above experiments show that Ki-67 is required for normal tumour growth and metastasis. To see whether Ki-67 knockout protects against tumourigenesis in vivo, we used a germline TALEN-disruption of Ki-67 (Mki67 2nt∆/2nt∆ ) that we generated (11) . We first employed a mouse model of colon carcinogenesis induced chemically by azoxymethane / dextran sodium sulphate (AOM-DSS) treatment (39) . We confirmed that DSS alone triggered similar inflammatory responses in mice of all genotypes (Fig. S4A,   B ). Furthermore, Mki67 2nt∆/2nt∆ mice have no apparent defects in immune cell proliferation and differentiation in response to haemolytic anaemia induced by phenylhydrazine treatment (Fig. S5 ). As expected, AOM-DSS efficiently induced colon tumours within 16 weeks in wild-type and Mki67 2nt∆/+ mice; however, no macroscopic lesions were observed in Mki67 2nt∆/2nt∆ mice ( Fig. 5A, B ). This suggests that Ki-67 is specifically required for initiation of tumourigenesis. To confirm this, we used a genetic model of intestinal tumourigenesis. We crossed Mki67 2nt∆/2nt∆ mice with Apc ∆14/+ mice, which rapidly develop tumours in the intestine due to loss of the second allele of the Apc tumour suppressor gene (40) . While, as expected, Apc ∆14/+ Mki67 2nt∆/+ mice formed multiple intestinal tumours, tumour burden was strongly reduced in Apc ∆14/+ Mki67 2nt∆/2nt∆ mice ( Fig. 5C, D) . Thus, Ki-67 is required for efficient initiation of tumourigenesis induced by chemical mutagenesis or loss of a tumour suppressor in vivo. We hypothesised that the altered transcriptomes that accompany loss of Ki-67 in non-transformed cells might hinder their oncogenic transformation. While testing this in vivo is not feasible, we found that overexpression of oncogenic RAS efficiently transformed wild-type NIH/3T3 cells, but not Mki67 -/-NIH/3T3 cells ( Fig. S6 ).
DISCUSSION
The above results show that Ki-67 is not required for cancer cell proliferation in vivo, but its expression critically influences all steps of tumourigenesis tested, including initiation, progression, metastasis and drug sensitivity. We present evidence that this is because Ki-67 is required to implement transcriptional programmes needed for tumour cell plasticity ( Fig. 5E ). This is indicated by the failure to generate intestinal tumours in Ki-67-mutant mice, the inability of cancer cells mutated for Ki-67 to induce angiogenesis, the extensive presence of EMT characteristics in epithelial cancer cells but their absence in cells lacking Ki-67, and the increased sensitivity of the latter to drugs.
A recent study in the human colorectal cancer cell line DLD-1 showed that Ki-67 knockout reduces the number of cells expressing the antigen CD133, commonly assumed to be a marker of cancer stem cells (CSC) (13) . However, in intestinal crypts, CD133 expression is not specific to stem cells, and CD133-negative cancer cells were equally capable of sustaining tumourigenesis in a long-term serial transplantation model (41) . Furthermore, the concept that CSCs are rare pre-existing populations of cells with hard-wired CSC properties, a model which emerged from xenograft experiments using sorted populations of hematopoietic stem cells, no longer appears valid, at least for solid tumours (42) . Lineage tracing experiments in the intestine showed that tumours arise from stem cells which divide rapidly, make up around 10% of the cell in intestinal crypts, and can be regenerated from non-stem cells (42) . A more recent concept is that epithelial cells are phenotypically plastic, in a manner dependent on EMT-inducing transcription factors (43) , with no such fixed entity as CSC or non-CSC.
Emerging evidence suggests that cells can reside in various phenotypic stages along the EMT-spectrum with concurrent expression of epithelial and mesenchymal traits, and that such hybrid states are important for carcinogenesis (34) (35) (36) . Our data showing that ALDH activity, which is a bona fide marker for intestinal stem cells and breast and colon CSC (29, 30) , is expressed by a significant fraction (≈10%) of WT epithelial cancer cells but far fewer (<3%) Ki-67 knockout cells, are consistent with this model.
Clues to the mechanism of action of Ki-67 are suggested by the fact that it is an intrinsically disordered protein (IDP) and behaves as a surfactant for mitotic chromatin (10) . We propose that these properties may also allow Ki-67 to regulate interphase chromatin, since, as we showed previously, heterochromatin is more dispersed in cells lacking Ki-67 (11) . Importantly, heterochromatin is a liquid-like compartment whose surface-tension properties depend partly on HP1 proteins (44, 45) , which bind directly to Ki-67 (46) . Such liquid-like compartments rely on proteins that can induce phase-separation, which often include IDPs (47) . Due to their conformational flexibility, IDPs can also act as hubs to bind multiple protein partners (48) , and we previously identified many general chromatin regulators interacting with Ki-67, including components of PRC1 and PRC2, REST, NuRD, NIF1, NuA4, MLL, SET1, NoRC and NCOA6 complexes (11) . Disrupting one such interactor, the PRC2 complex, partially, but not fully, rescued EMT traits in Ki-67 mutant cancer cells, consistent with the idea that Ki-67 acts through multiple chromatin regulatory complexes. We speculate on several ways in which Ki-67 might generally confer transcriptome plasticity to cells in response to environmental conditions. First, it might directly sequester and release general chromatin regulators, providing a pool of these factors for rapid cellular adaptation. In this model, Further studies will be required to test these models and define the exact biochemical mechanisms by which Ki-67 confers transcriptional plasticity to cells.
In conclusion, Ki-67, which is universally expressed in proliferating cells, enables multiple steps in carcinogenesis in different cancer types by promoting global transcriptional programmes. Therapeutic targeting of Ki-67 itself will likely be challenging, since it is an IDP with no intrinsic enzyme activity. However, it could be of therapeutic benefit to inhibit its effectors in control of cellular plasticity. 
MATERIALS AND METHODS

Cell lines and mice
Animal studies
All animal experiments were performed in accordance with international ethics standards and were subjected to approval by the Animal Experimentation Ethics Committee of Languedoc Roussillon (n°APAFIS#8637-2017012311188975v3). pUC57-U6-sgRNA (#51132, Addgene); Cas9-VP12 (#72247, Addgene), modified by adding T2A-GFP at the C-terminal end (gift from Edouard Bertrand, IGMM).
Antibodies and plasmids
CRISPR/Cas9-mediated genome editing
The sgRNAs targeting mouse Mki67 exon 3 or human MKI67 exon 6 and non-targeting control sequences were previously designed (49) , and cloning of the target sequence into the LentiCRISPRV2 lentiviral vector was conducted as described (54) . Lentiviruses FlowJo® software was used for analysis.
Mammosphere assay
The mammosphere formation assay was performed as previously described (50) . Briefly, 500 cells were plated per well in a low-adherence 96-well plate coated with poly-2hydroxyethyl-methacrylate (poly-Hema). After 7 days in culture (37°C, 5% CO 2 ), images of formed mammospheres were acquired and counted using automated high-content microscopy analysis (Cellomics, Thermo).
Aldehyde Dehydrogenase 1 (ALDH1) activity
ALDH1 enzymatic activity was determined using the ALDEFLUOR kit (Stem Cell Technologies) according to the manufacturer instructions. For each sample, half the cell/substrate mixture was treated with diethylaminobenzaldehyde (DEAB; ALDH inhibitor). ALDEFLUOR/DEAB treated cells were used to define negative gates. FACS was performed with ≥10 5 cells.
Xenografts
Animals were housed in the animal facility of IGMM and were maintained in a pathogenfree environment and fed ad libitum.
To generate primary tumours, 10 6 cells (4T1) or 3x10 6 At the end of the experiment, following sacrifice, primary tumours were excised and fixed over-night in neutral buffered formalin (10%) before paraffin embedding (see above). IHC analysis of Ki-67 expression of the different tumour tissue sections was conducted as described above.
Visualisation of lung metastases
Dissected lungs were stained with 15% India Ink diluted in distilled water, and subsequently washed with 5 ml Fekete's solution (40 ml glacial acid acetic, 80 ml formalin, 580 ml ethanol 100%, 200 ml water). A binocular microscope connected to a digital camera was used to visualise and count the metastatic nodules.
Automated drug library screen
We performed an initial screen of all 1,280 FDA-approved drugs in the Prestwick Chemical Library (Prestwick Chemical, Illkirch-Graffenstaden, France) at 10 μM in white clear-bottom 96-well plates. Briefly, we prepared seeding solutions at a density of 2 × plates using a Multidrop Combi Dispenser (Thermo Scientific™). Next, we prepared 1x treatment solutions of the Prestwick compounds in DMEM complete medium at a concentration of 10 μM using a Tecan EVO200 robotic liquid handling system (Tecan Trading AG). We removed medium from the pre-seeded 96-well plates and we dispensed 100 μL of 1x treatment solutions using the Tecan robot. We incubated plates at 37°C, 5% CO 2 for 48 h in an automated incubator (Cytomat, Thermo Scientific™) associated with the Tecan robot. After treatment, cell survival was determined using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega Corporation) in accordance with the manufacturer's instructions. Luminescence signal was automatically measured with a Tecan Infinity F500 microplate reader (Tecan Trading AG). "Hits" were identified applying the Z-score statistical method (see statistical analysis section). The same method was used for subsequent dose-response experiments on selected "hits".
Induction of anemia with PHZ
Anemia was induced in adult Mki67 2nt∆/2nt∆ mice and littermate controls (Mki67 +/2nt∆ ) by injection of 40 mg/kg phenylhydrazine (PHZ) on days 0, 1, and 3. Animals were sacrificed on day 5 and blood, spleen and bone marrow were collected. Hematocrit was measured as previously described (51) . Cell suspensions were generated and immunophenotyping performed by flow cytometry. Cells were stained with Sytox blue or Live/dead fixable viability dye (Life Technologies and eBioscience, respectively) together with the appropriate conjugated anti-CD3, CD62L, CD4, CD8, CD44, CD25, Colony formation assay 3T3 wild-type (WT) and two Ki-67 TALEN-mutant clones were transduced with either empty control or H-Ras G12V expressing retroviruses. After verification of Ras G12V expression, cells were seeded at 10 5 cells/well (6 well-plate) in triplicate and allowed to grow for 2-weeks (media were changed every 2 days). Cells were then fixed (4% formaldehyde) and stained with 0.5% (w/v) crystal violet to visualise the colonies formed.
RNA sequencing library preparation
Total RNA was extracted using Trizol (Life Technologies) following manufacturer's instructions from wild type and two clones of 4T1 Ki-67 knockout cell lines. RNA integrity was analysed on Agilent 2100 bioanalyzer. For library preparation, cDNA synthesis was performed on rRNA-depleted samples using the TruSeq Stranded Total RNA Library Preparation (RS-122-2301). All sequencing libraries were prepared in two or three biological replicates. Indexed cDNA libraries were sequenced by MGX (Montpellier) on Illumina HiSeq2000 with a single 50 bp read and a 10 bp index read.
Sequencing of cDNA libraries and data processing
FastQC was used to perform quality control of the sequencing. Using the tool STAR 2.6.0a (2) , all the reads that passed the quality control were aligned to the mouse reference genome (GRCm38.p6) and the counts per gene were quantified. The release 93 of the Ensembl mouse genome annotations were used for establishing the coordinates of each gene and their transcripts. Differential expression analysis was performed in R using the DESeq2 (2) library embedded in an in-house script. After normalization of the read counts per gene, a negative binomial generalised linear model was fitted considering single factor design for assessing the differential expression between Mki67 knockout and wild-type samples. Gene set enrichment analysis of the 4T1 Mki67 -/cell line vs WT cell line was performed using the javaGSEA (3) desktop application with a log-fold-change pre-ranked gene list.
Gene set enrichment for transcription factors.
The gene set enrichment was performed over the ENCODE and ChEA Consensus TFs from ChIP-X gene set, which contains consensus target genes for transcriptions factors present in ENCODE and ChEA databases. The p value was computed with the Fisher Exact test and then adjusted for multiple hypotesis testing in order to obtain the FDR (false discovery rate) adjusted p-value.
Statistical analysis
Significant differences between the different experimental groups were tested using an were considered to indicate a statistically significant result.
Data availability
All RNA-seq raw data will be deposited in GEO and will be publicly available prior to publication of the manuscript.
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